Belantamab Mafodotin, Bortezomib, and Dexamethasone for Multiple Myeloma
Hungria V, et al.
New England Journal of Medicine
June 2024
Authors and Affiliates
V. Hungria, P. Robak, M. Hus, V. Zherebtsova, C. Ward, P.J. Ho,
A.C. Ribas de Almeida, R. Hajek, K. Kim, S. Grosicki, H. Sia, A. Bryant,
M. Pitombeira de Lacerda, G. Aparecida Martinez, A.M. Sureda Balarí, I. Sandhu,
C. Cerchione, P. Ganly, M. Dimopoulos, C. Fu, M. Garg, A.-O. Abdallah, A. Oriol,
M.E. Gatt, M. Cavo, R. Rifkin, T. Fujisaki, M. Mielnik, N. Pirooz, A. McKeown,
S. McNamara, X. Zhou, M. Nichols, E. Lewis, R. Rogers, H. Baig, L. Eccersley,
S. Roy‑Ghanta, J. Opalinska, and M.-V. Mateos, for the DREAMM-7 Investigators
Clinica São Germano (V.H.) and Hospital das Clínicas and Instituto do Câncer do Estado de
São Paulo, Universidade de São Paulo (G.A.M.), São Paulo, Centro de Pesquisa e Ensino em Saúde de Santa Catarin, Florianópolis
(A.C.R.A.), and Universidade da Região de Joinville and Centro de Hematologia e Oncologia, Joinville (M.P.L.) — all in Brazil; Medical
University of Lodz, Lodz (P.R.), Medical University of Lublin, Lublin (M.H., M.M.), and the Medical University of Silesia, Katowice (S.G.)
— all in Poland; Gorodskaya Klinicheskaya Bol’nitsa Imeni Saint Petersburg Botkina, Moscow (V.Z.); the Royal North Shore Hospital
(C.W.) and Liverpool Hospital (A.B.), Sydney, Royal Prince Alfred Hospital and University of Sydney, Camperdown, NSW (P.J.H.), and
Pindara Private Hospital, Gold Coast, QLD (H.S.) — all in Australia; the Department of Hematooncology, University Hospital Ostrava,
and Faculty of Medicine, University of Ostrava, Ostrava, Czech Republic (R.H.); Sungkyunkwan University and Samsung Medical Center,
Seoul, South Korea (K.K.); Institut Català d’Oncologia–L’Hospitalet de Llobregat–Barcelona, Barcelona (A.M.S.B.), Institut Català
d’Oncologia and Josep Carreras Research Institute, Hospital Germans Trias i Pujol, Badalona (A.O.), and Hospital Universitario de
Salamanca, Instituto de Investigación Biomédica de Salamanca, Centro de Investigación del Cáncer, Ciberonc, Salamanca (M.-V.M.)
— all in Spain; Cross Cancer Institute, Edmonton (I.S.), and GSK, Mississauga (H.B.) — both in Canada; the Hematology Unit, Istituto
Romagnolo per lo Studio dei Tumori “Dino Amadori,” IRST IRCCS, Meldola (C.C.), and IRCCS Azienda Ospedaliero–Universitaria
di Bologna, Istituto di Ematologia “Seràgnoli,” Bologna (M.C.) — both in Italy; Christchurch Hospital, Christchurch, New Zealand
(P.G.); National and Kapodistrian University of Athens, Athens (M.D.); the First Affiliated Hospital of Soochow University, Suzhou,
China (C.F.); University Hospitals of Leicester NHS Trust, Leicester (M.G.), GSK, Stevenage (A.M., S.M.), and GSK, London (L.E.) — all
in the United Kingdom; University of Kansas Cancer Center, Fairway (A.-O.A.); the Department of Hematology, Hadassah Medical
Center, Faculty of Medicine, Hebrew University of Jerusalem, Jerusalem, Israel (M.E.G.); Rocky Mountain Cancer Centers–Denver–Midtown,
Denver (R. Rifkin); Matsuyama Red Cross Hospital, Matsuyama, Japan (T.F.); GSK, Upper Providence, PA (N.P., X.Z., R. Rogers,
S.R.-G., J.O.); and GSK, Durham (M.N.), and GSK, Research Triangle Park (E.L.) — both in North Carolina